World Health Organization
Essential Drugs and Medicines Policy
Hans V. Hogerzeil1 (Editor)
Karen I. Barnes2
Rob H. Henning3
Yunus E. Kocabasoglu3
Anthony J. Smith5
Rob S. Summers6
Theo P.G.M. de Vries7
with contributions from Hannelie Meyer, Sule Oktay, Budiono Santoso and Sri Suryawati
1 WHO Department of Essential Drugs and Medicines Policy, Geneva, Switzerland
2 WHO Collaborating Centre for Drug Policy, Information and Safety Monitoring, Department of Clinical Pharmacology, Medical School, University of Cape Town, Cape Town, South Africa
3 WHO Collaborating Centre for Pharmacotherapy Teaching and Training, Department of Pharmacology and Clinical Pharmacology, Medical Faculty, Groningen University, Groningen, The Netherlands
4 WHO, South African Drug Action Programme, Pretoria, South Africa
5 WHO Collaborating Centre for Pharmacotherapy Teaching and Training, Discipline of Clinical Pharmacology, Medical School, Newcastle, Australia
6 WHO Collaborating Centre for Pharmacy Curriculum Development and Rational Use of Drugs, School of Pharmacy, Medical University of Southern Africa, Pretoria, South Africa
7 Department of Pharmacology, Medical Faculty, University of Amsterdam, Amsterdam, The Netherlands
The support of the following persons in reviewing earlier drafts of this book is gratefully acknowledged:
F. Danish (Kabul, Afghanistan), A. Haeri (Tehran, Islamic Republic of Iran), A. Helali (Algiers, Algeria), K.K. Kafle (Kathmandu, Nepal), R.O. Laing (Boston, USA), J.C. Lombard (Sovenga, South Africa) and I. Moodley (Johannesburg, South Africa).
© World Health Organization 2001
This document is not a formal publication of the World Health Organization (WHO), and all rights are reserved by the Organization. The document may, however, be freely reviewed, abstracted, reproduced and translated, in part or in whole, but not for sale nor for use in conjunction with commercial purposes.
The views expressed in documents by named authors are solely the responsibility of those authors.
Printed in France